- 15-01-2020AVROBIO Announces Clinical and Regulatory Progress For Gaucher Disease Program
- 10-01-2020PR001 Administered to International Type 2 Gaucher Disease Patient Via Compassionate Use Pathway
- 08-01-2020Prevail Therapeutics Is Recruiting Patients For PROPEL, a Clinical Trial Testing An Investigational Gene Therapy Called PR001 to Treat Parkinson’s Disease In People with GBA Mutations
- 17-12-2019December 2019 Newsletter
L’EGA è un gruppo ombrello pan europeo che rappresenta gli interessi dei pazienti Gaucher e quelli dei gruppi di pazienti Gaucher non a scopo di lucro in tutta Europa e altrove nel mondo.
Italiano ▼ login ▼
COLLEGATI AD UNO DEI NOSTRI 41 PAESI MEMBRI PER SOSTEGNO, CONSIGLIO E NOTIZIE A LIVELLO LOCALE
Vedi mappa
chiudi- Finland
- Norway
- Sweden
- Estonia
- Russian Federation
- Latvia
- Denmark
- Lithuania
- United Kingdom
- Netherlands
- Ireland
- Poland
- Germany
- Belgium
- Czech Republic
- Ukraine
- Slovakia
- Luxembourg
- Moldova, Republic of
- Austria
- France
- Switzerland
- Romania
- Slovenia
- Croatia
- Serbia
- Bosnia & Herzegovina
- Bulgaria
- Italy
- Macedonia, the Former Yugoslav Republic of
- Spain
- Greece
- Israel
Sostieni L’EGA
Sostieni l’EGA